Researcher

    Richard L. Momparler , Ph.D.

    richard.l.momparler@umontreal.ca
    Richard L. Momparler
    Research Axis
    Viral and Immune Disorders and Cancers
    Research Theme
    Cancer: genetic and molecular mechanisms, and new therapies
    Address
    CHUSJ - Centre de Recherche

    Phone
    514 345-4931 #6140

    Fax
    514 345-4801

    Title

    • Professor, Department of Pharmacology, University of Montreal, 1985.
    • Researcher, CHU Sainte-Justine Research Center, 1977.

    Education

    • Postdoctoral Fellow, Biochemistry, International Laboratory Genetics & Biophysics, Naples, Italy, 1966.
    • Postdoctoral Fellow, Pharmacology, Yale University, 1965.
    • PhD, Pharmacology, University of Vermont, 1964.
    • BSc, Biology, Michigan State University, 1957.

    Research Interests

    Richard Momparler’s main research interests relate to the evaluation of various experimental agents in cancer chemotherapy. Richard Momparler was the first to reveal Ara-C’s mechanism of action as a chain terminator. He was also the first to propose the use of high-dose Ara-C in acute leukemia therapy. Through investigations using mouse models he discovered that 5-azadeoxycytidine (5-aza) was a more potent antileukemic agent than Ara-C. In collaboration with his team and hematologists working at the CHU Sainte-Justine, he was the first to conduct a clinical trial on 5-aza in children suffering from leukemia and demonstrate that 5-aza is an active agent. During cancer development many tumor suppressor genes are inactivated by aberrant DNA methylation. Richard Momparler’s laboratory was the first to demonstrate that methylation of retinoic acid receptor beta (RARb) inactivated tumor suppressor genes in colon and breast cancer in humans.

    In collaboration with Joseph Ayoub at Notre-Dame Hospital, his team conducted a clinical trial on the effect of 5-aza in patients with advanced lung cancer and demonstrated that it is an active antitumor agent. More recently, Richard Momparler’s team has investigated other histone deacetylation inhibitors for use in combination with 5-aza. Current data suggest that these interesting inhibitors enhance the antineoplastic activity of 5-aza and that the use of 5-aza in combination with these agents would be effective in future clinical trials conducted on cancer patients.

    Career Summary

    • Associate Professor, Department of Pharmacology, University of Montreal, 1977-1984.
    • Associate Professor, Department of Pharmacology, University of Southern California, Los Angeles, 1972-1976.
    • Assistant Professor, Department of Biochemistry, McGill University, 1967-1971
About this page
Edited by Hoffmann Maude

Created on 9/18/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine